STUDY DESIGN AND METHODS:
This was a retrospective monocentre study of all patients followed up for parvovirus B19 infections in which IUETs were performed. An IUET was indicated when foetal hydrops was observed and/or when severe foetal anaemia was diagnosed though an elevation in the middle cerebral artery peak systolic velocity. The characteristics of each pregnancy and the neonatal outcomes were studied until hospital discharge.
RESULTS: Thirty-five IUETs were performed in 26 foetuses. The median gestational age of the first IUET was 22.6 weeks. Only one foetal bradycardia incidence was recorded during the procedure. Three medical pregnancy terminations were observed in our series, secondary to severe cerebral anomalies confirmed in the magnetic resonance imaging. Five in utero deaths occurred, in which 2 of the foetuses underwent multiple IUETs. All the neonates had normal haemoglobin levels at birth, and none were transferred to the neonatal intensive care unit. The overall survival rate was 70%.
CONCLUSION: IUETs exhibit a survival rate similar to that of simple intrauterine transfusions in foetal parvovirus infection cases. P arvovirus B19 is a small seasonal variation virus with a spring resurgence. One-half of childbearingage women are susceptible to B19 infections; the other half are protected by an acquired immunity. 1 In cases of contamination, the risk of a maternal infection rises to 21%. 2 The peak incidence occurs during the second trimester, at around 22 weeks of pregnancy. 3 The fetal infection remains asymptomatic in two-thirds of the cases.
In utero, this virus may cause severe bicytopenia, particularly in the fetal red blood cells and platelets. Moreover, it has an affinity for myocardial cells. 4 Thus fetal hydrops may be explained by two mechanisms: erythroid precursor cell apoptosis causing severe anemia and associated viral myocarditis.
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The antenatal care in these cases relies on close monitoring, with middle cerebral artery peak systolic velocity (MCA-PSV) measurements and an in utero transfusion (IUT) if necessary. This management reduces the mortality rate when compared with abstention. 5 It also prevents brain injuries that can be detected either by ultrasound or magnetic resonance imaging (MRI) findings. 6 In France, 17% of ABBREVIATIONS: Ig = immunoglobulin; IUET = intrauterine exchange transfusion; IUT = in utero transfusion; MCA-PSV = middle cerebral artery peak systolic velocity; MoM = multiple of median; PROM = premature rupture of membranes the IUTs are performed for parvovirus B19 infections. 7 Nonetheless, complications occur in 1.2% to 3.4% of IUT procedures. 8, 9 These complications occur more frequently in hydrops cases, probably due to vascular overload, especially myocardial dysfunction. Radunovic et al 10 confirmed a poor IUT tolerance in hydrops cases with large and acute hematocrit increases. Therefore, intrauterine exchange transfusions (IUETs) were proposed to reduce the transfusion volume and, at the same time, to avoid a vascular overload. 10, 11 IUETs and simple transfusions have been compared in alloimmunization cases 12 but never in parvovirus B19 cases. The aim of this study was to evaluate the obstetrical and neonatal outcomes after IUET treatment in parvovirus infection cases with anemia.
MATERIALS AND METHODS
This retrospective study included all the patients who underwent IUETs for fetal parvovirus infections between January 1992 and December 2016 in one center (Lille, France). This study was approved by the French Data Protection Authority (DEC16-209). These patients were referred in our hospital for fetal hydrops or an increased MCA-PSV. 13, 14 A maternal blood test was performed to determine the anemia etiology (red blood cell immunization antibodies, Kleihauer test, and parvovirus B19 and cytomegalovirus serological tests). A parvovirus B19 infection was suspected based on the maternal serology with immunoglobulin (Ig)M positivity combined with a little IgG positivity, or their negativity. The infection was confirmed via a polymerase chain reaction analysis of the amniotic fluid. IUETs were indicated in the cases with fetal hydrops (i.e., accumulation of fluid in at least two fetal compartments including ascites, pericardial effusion, pleural effusion, subcutaneous effusion, placental thickness, and hydramnios 15 ) or an MCA-PSV greater than 1.5 to 1.55 multiple of the median (MoM). [16] [17] [18] The IUETs were performed as previously described 19, 20 using a 20G needle. They were performed in an operating room with at least two obstetricians, one pediatrician, and one anesthesiologist in case maternal analgesia was needed (sedation or epidural). The needle was inserted preferentially in the umbilical vein, proximal to the placentaumbilical junction, under ultrasound guidance. The anemia severity was assessed using the hemoglobin level and hematocrit measured at the beginning of the procedure (Stat Profile pHOx, Nova Biomedical). To limit complications related to fetal movements, a curare (Atracurium, Pfizer, 0.2 mg/kg) was first injected. The administration volume calculation was made using the estimated fetal weight (EPW), initial hemoglobin (Hbi), final expected hemoglobin (Hbf ), and Hb of the transfusion unit (Hbu) according to this formula:
The blood component statuses were evaluated during the IUET. The protocol is that after each transfusion of 30 mL were transfused, 20 mL are withdrawn until Hb increases to 12 to 13 g/dL. Fetal ultrasound monitoring was performed continuously throughout the IUET, and it was performed before and after the IUET in the women with more than 26 weeks of gestation. After the procedure, patients stayed in the hospital for 1 or 2 nights until MCA-PSV was normalized and fetal monitoring (if performed) was satisfactory. After that, patients were followed weekly for 3 months, with an ultrasound checkup including MCA-PSV measurement at each appointment. The IUET complications were recorded, such as a premature rupture of membranes (PROM), preterm delivery within 7 days of the transfusion, chorioamnionitis, emergency cesarean delivery due to fetal distress within 24 hours of the procedure, fetal death, and neonatal death.
A second IUET was indicated if the MCA-PSV rose above 1.5 MoM again, with or without a serosal effusion association. After the IUET, the patient was monitored closely at our center for 2 weeks. Since 2003, every fetus with a hydrops diagnosis or an initial Hb level lower than 5 g/dL has undergone a cerebral MRI at approximately 30 weeks of gestation. In our center, we found that MRI may better detect brain lesions than ultrasound in the management of severe fetal anemia. 6, 21 Fetal MRI scans were assessed by a specialist in fetal ultrasound and a neuroradiologist MRI expert as previously published. 21, 22 After this period, patients were followed at their initial centers. The outcomes were assessed though the medical files including the clinical, biological, and echographic data. The overall survival rate was based on the number of live infants discharged from the maternity department.
Statistics
The qualitative variables were expressed as the frequency and percentage, and the quantitative variables were expressed as the median and interquartile range or the mean and standard deviation, depending on the cohort size. This was only a descriptive study, with no statistical testing.
RESULTS
A total of 35 IUET procedures were performed in 26 patients. Table 1 summarizes the characteristics of the study population. The parvovirus B19 infections were mostly discovered during the second routine ultrasonography (23 cases [88%]), and the other three cases were discovered at 28 or 30 weeks when an additional ultrasound was performed. The indications of those supplementary ultrasonographies were a threatened preterm labor, a fetal growth follow-up, and an incomplete morphological scan. No diagnosis was made after clinical signs or a serological test follow-up.
The most common ultrasonographic sign was fetal hydrops (n = 23 [88%]). Ascites was found in the other three situations, combined with cardiomegaly in two cases and a hyperechogenic fetal bowel in one case. The MCA-PSV was evaluated in 16 fetuses, with a mean pretransfusion result of 1.96 MoM (AE0.4). Cases before 1997 did not have an MCA-PSV evaluation. Five of the fetuses (19.2%) required multiple transfusions: three (11.5%) underwent two procedures, and two (7.6%) underwent three procedures. The average time between the two IUETs was 8.5 days (AE3.4 d) . Only one complication occurred during the IUET (fetal bradycardia with a spontaneous recovery). A second insertion of the needle was needed in 22% of the IUET procedures. Median duration of IUET was 20 minutes (AE 9.3 min). No cases of PROM, preterm labor, or an emergency cesarean delivery occurred after IUETs. Among the fetuses born alive, the mean gestational age at birth was 37.4 weeks (AE3.4 wk). The average birthweight was 2962 g (AE461 g), and no patients required hospitalization in the intensive care unit. Table 2 details the nonfavorable outcomes. Three medical pregnancy terminations were performed at the parents' request due to fetal neurologic complications (cases 3, 4, and 8). In case 3, cerebral hypoxia was noticed along with signs of cerebral atrophy associated with periventricular leukomalacia. Case 4 exhibited periventricular leukomalacia combined with cerebellar hypotrophy. In case 8, there was cerebral atrophy with maternal mirror syndrome. The initial hemoglobin levels were 2.7 g/dL, 1.4 g/dL, and 2.7 g/dL, respectively. Cases 3 and 4 underwent two procedures at 7 and 9 days. The cerebral abnormalities were diagnosed at 34 weeks for case 3 (8.5 weeks after the IUET), 26 weeks for case 4 (1 wk after the IUET), and 32 weeks for case 8 (7 wk after the IUET). The cerebral anomalies were first suspected in the echography and then confirmed by the MRI in every case. Five in utero deaths were observed in our study population. No procedural complications were recorded in these cases. The initial hemoglobin level was 2.2 g/dL (AE1.3 g/dL), and the final hemoglobin level was 11.5 g/dL (AE2.6 g/dL). Death occurred on average within 5.8 days after the procedure. Each of the fetuses presented with fetal hydrops; four of them had cardiomegaly, and the last one exhibited severe fetal growth restriction. The overall survival rate in the study population was 70% (18/26).
DISCUSSION
A parvovirus B19 infection causes fetal anemia that can lead to hydrops. The treatment relies on an IUT that may cause a vascular overload and fetal complications, especially in associated myocardial failure cases that occur frequently in parvovirus infections. In our center, we proposed IUET to avoid vascular overload. To the best of our knowledge, this was the first study to evaluate IUETs in parvovirus infection cases; however, we observed no benefit when compared with IUTs, according to the literature. 23 The mortality related to parvovirus B19-induced anemia remains higher than that in alloimmunization cases: 10.2% 24 versus 7%. 19 This difference can be explained by the characteristics of the parvovirus B19 infection itself. Fetal anemia is often diagnosed incidentally, and it is almost always severe and associated with fetal hydrops. When fetal hydrops occurs, the prognosis is even worse; the mortality rises to 34% in a parvovirus infection 3 and 20% in alloimmunization. 26 Moreover, this virus has a special affinity for myocardial cells, and it can induce myocardial failure by itself. This underscores the need for a limited target Hg level for the transfusion, even if this means repeating the procedure several days later. In our study, 27% of the fetuses underwent a second or a third transfusion. This rate varied from 0% to 38% in the literature. [27] [28] [29] [30] [31] [32] Few series have been published describing parvovirus infections and the neonatal outcomes after transfusions. Table 3 summarizes six of the largest series [27] [28] [29] [30] [31] [32] including the main hematologic data, management, survival rates, and outcomes. These studies described fetuses with confirmed parvovirus B19 infections, almost always with fetal hydrops. In those studies, simple transfusions were performed, with or without associated platelet transfusions, and the survival rates ranged from 54% to 84% (70% was observed in our study). Therefore, there were no differences in the survival rates whether a simple transfusion or an exchange transfusion was performed.
In our series, we observed 19% in utero fetal deaths when compared with 17% to 33% in the simple transfusion cases. 29, 32 In the severe anemia cases, the most common complication in the neonates born alive was the occurrence of neurologic lesions. In an alloimmunization context, Even if our study was the first to evaluate IUETs in parvovirus infection cases, it does have some limitations. First, because of the rarity of parvovirus B19 infections, our data were spread over a long period of time (24 years). Moreover, we could not study the neurodevelopmental outcomes for every live birth case because the births occurred at different centers in our region, without organized neurologic follow-ups.
CONCLUSION
In our series, the IUET exhibited a survival rate similar to literature cases of simple IUT in fetal anemia cases secondary to a parvovirus infection. It is the first study to suggest that there is no conclusive evidence that IUET has an advantage over IUT in the treatment of pregnancies affected by parvovirus B19. Unfortunately, fetal mortality and severe neurologic lesions remain high in cases of anemia due to a parvovirus B19 infection.
